This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
The results presented in this study were in part generated through TCGA (dbGaP Study Accession: phs000178; Principal Investigator: JPM). Requests for additional information should be made to the corresponding author.
References
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–22.
Qian M, Zhang H, Kham SK, Liu S, Jiang C, Zhao X, et al. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 2017;27:185–95.
Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–95.
Yao TP, Oh SP, Fuchs M, Zhou ND, Ch’ng LE, Newsome D, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 1998;93:361–72.
Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci USA. 2002;99:14789–94.
Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood. 1997;90:4699–704.
Ohnishi H, Taki T, Yoshino H, Takita J, Ida K, Ishii M, et al. A complex t(1;22;11)(q44;q13;q23) translocation causing MLL-p300 fusion gene in therapy-related acute myeloid leukemia. Eur J Haematol. 2008;81:475–80.
Duhoux FP, De Wilde S, Ameye G, Bahloula K, Medves S, Légé G, et al. Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes. Leuk Res. 2011;35:e18–20.
Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, et al. Enhancer activity requires CBP/P300 bromodomain-dependent histone H3K27 acetylation. Cell Rep. 2018;24:1722–9.
Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24:1799–804.
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–10.
Cheng G, Liu F, Asai T, Lai F, Man N, Xu H, et al. Loss of p300 accelerates MDS-associated leukemogenesis. Leukemia. 2017;31:1382–90. 2017/06/01
Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, et al. Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Cancer Res. 2015;75:5106–19.
Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, et al. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Adv. 2020;4:4124–35.
Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, et al. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS ONE. 2013;8:e55481.
Acknowledgements
We thank The BEAT-AML Master trial, TCGA, and The German-Austrian study group for sharing clinical and genomic data of patients. This work was supported by the Henry and Marilyn Taub Foundation, grants R01HL118281, R01HL123904, R01HL132071, R35HL135795 (all to JPM).
Author information
Authors and Affiliations
Contributions
SK conceived the study, analyzed the data, and wrote the paper. CMK, WW, SH, and MM performed the genomic sequencing and analyzed genomic data. VA collected clinical information and analyzed whole genome sequencing data. YN, HA, CG, and TH provided patient samples and clinical information. HJR reviewed hematopathology. SP and VV contributed to data analysis, interpretation of the results, wrote and critically reviewed the manuscript. YS and TH contributed to interpretation of the results and critically reviewed the manuscript. JPM conceived the study, designed the experiments, contributed to data analysis, interpretation of the results, and wrote the manuscript. All authors discussed the results and revised the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Kongkiatkamon, S., Pagliuca, S., Adema, V. et al. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia 36, 1185–1188 (2022). https://doi.org/10.1038/s41375-021-01479-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01479-9